Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visbiome Extra Strength for Inflammation in HIV-Infected Patients on ART
NCT02706717Phase 2Completed
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Visbiome in human immunodeficiency virus type 1 infection (HIV-1). Started Apr 2016; status: completed.
02
Drugs
Visbiome
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02706717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706717.